Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about the safety of AMD3100 (plerixafor)
and G-CSF (filgrastim) in combination with fludarabine, busulfan, and an allogeneic blood
stem cell transplant. This treatment will be studied in patients with acute myeloblastic
leukemia (AML), myelodysplastic syndromes (MDS), or Chronic myelogenous leukemia (CML).